Funding for this research was provided by:
National Cancer Institute (P30CA008748)
Article History
Received: 25 August 2023
Accepted: 22 September 2023
First Online: 24 October 2023
Declarations
:
: CF and SC have no pertinent conflicts or disclosures to report. MS reports serving as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., Omeros Corporation, and Amgen, Inc.; served on ad hoc advisory boards for Kite—A Gilead Company; and received honoraria from i3Health, Medscape, and CancerNetwork for CME-related activity.
Free to read: This content has been made available to all.